📅 PUBMED DAILY TRIAGE — 2026-05-31

Window: 2026-05-30T09:00:00Z → 2026-05-31T09:00:00Z (CRDT)
Topics scanned: 10 | Articles reviewed: ~56 unique candidates | Classified: 14
High priority: 4 | Standard: 10 | Low/archive: ~42 | Unsolicited finds: 1
Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection / Liquid Biopsy & Genomics/Precision Medicine

TR-001 · PMID 42216432 · A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors. · 8/10 🟠
Fujita T et al. · Cancer (Jun 2026) · n=2040 · Retrospective real-world cohort
→ CHIP (detected by liquid biopsy panel) in 25.7% of advanced solid tumor patients receiving ICI therapy; CHIP-positive patients had significantly longer ICI TTD (10.1 vs 7.9 months, HR 0.81, p=.005), with TET2 mutations independently driving benefit (HR 0.77); no increase in grade ≥3 irAEs. CHIP is already co-detected on many clinical liquid biopsy panels — this finding is immediately actionable for ICI patient selection without additional infrastructure.

Novel Therapeutics — Rare/Pediatric Cancers

TR-002 · PMID 42216567 · Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human. · 8/10 🟠
Song M et al. · Oncoimmunology (May 2026) · n=2 patients (clinical) + extensive preclinical · Phase I ongoing (NCT06631391)
→ First translational study of UCB-derived NK cells combined with anti-GD2 antibody in high-risk relapsed/refractory neuroblastoma; 2 patients achieved complete and partial responses with no additive toxicity; mechanistically, anti-GD2 induced a "high activating-low inhibitory" NK cell phenotype. Only 2 clinical cases, but strong preclinical foundation, Sun Yat-sen cancer center, active Phase I trial launched — this is an early-signal finding for a pediatric cancer with very limited options.

Novel Therapeutics — Targeted Therapy / NSCLC

TR-003 · PMID 42216441 · Amivantamab in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry. · 7/10 → HIGH via NOVEL_TREATMENT 🟠
Passiglia F, Novello S et al. · Cancer (Jun 2026) · n=119 (64 receiving amivantamab) · Multicenter retrospective observational
→ Real-world Italian registry confirms CHRYSALIS efficacy: ORR 37.5%, mPFS 9.6 months, mOS 16.9 months for amivantamab in EGFRex20ins NSCLC; grade ≥3 TRAEs only 10.9%; intracranial mPFS 11.6 months in 23 brain-met patients is the standout new finding — notable activity at a sanctuary site in a population where brain metastases are common and hard to treat.

Cardiovascular-Metabolic / Rare Diseases

TR-004 · PMID 42216490 · Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM. · 8/10 🟢
Fontana M, Gillmore JD, Damy T et al. (UCL, National Amyloidosis Centre + international) · Eur J Heart Fail (May 2026) · n=611 · Post-hoc of phase 3 RCT (ATTRibute-CM)
→ Outpatient worsening HF (loop diuretic escalation) occurred in 47% of ATTR-CM patients and substantially increased mortality/hospitalization risk (HR 1.95 for ACM+CVH); acoramidis reduced outpatient worsening HF by 41% (HR 0.59, 95% CI 0.46–0.75), with separation emerging at day 30. In a disease where acoramidis is approved in several countries, this data establishes loop diuretic monitoring as an early clinical warning signal and supports early treatment initiation.

🟢⚪ STANDARD (4–7) — Top by Topic

Hematologic Malignancies

• TR-005 · PMID 42216241 · Improving salvage regimens prior to ASCT in relapsed/refractory Hodgkin's lymphoma: novel therapy era updates. · 6/10 · Treatment Innovation
  Kim JL, Micallef IN (Mayo Clinic) · Expert Rev Hematol · Review — PD-1-based salvage now preferred; ctDNA-guided ASCT omission is the next frontier; novel agents urgently needed post-BV+PD-1.

• (PMID 42216561 / Br J Haematol — AML ineligibility criteria [Integrated Comorbidity-ECOG-Age]: scored 3/10 title-only, no abstract available; logged but not classified)

AI/ML in Clinical Diagnostics

• TR-006 · PMID 42216673 · Multimodal machine learning for early risk stratification of post-stroke cognitive impairment. · 6/10 · Diagnostics / Early Detection
  Zheng X et al. · J Alzheimers Dis · n=1070 AIS · Stacking ensemble (AUC 0.9972 internal → 0.9049 external); key predictors: infarct volume, cortical lesions, medial temporal atrophy, NIHSS. Caution: implausibly high internal AUC suggests potential overfitting; external validation more clinically credible.

Novel Therapeutics (Immunotherapy / Targeted)

• TR-007 · PMID 42216493 · Envafolimab + Rh-endostatin in PD-L1+ NSCLC (Endouble phase 2). · 6/10 · Treatment Innovation
  Dong C et al. · Cancer · n=33 · ORR 48.5%, mPFS 12.3 months; subcutaneous PD-L1 inhibitor; small but promising; exploratory biomarkers (MMP1, TNFRSF6B).

• TR-014 · PMID 42216534 · DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer. · 4/10 · Drug Development
  Wu Y et al. · Front Biosci · Review of DDR pathway-targeted strategies for anthracycline resistance.

Cardiovascular-Metabolic

• TR-010 · PMID 42216489 · Cardio-Obstetrics Care: Challenging Scenarios in Heart Failure and Future Directions. · 4/10 🟡 UNDERSERVED_POPULATION
  Sliwa K, Bauersachs J et al. · Eur J Heart Fail · Review; addresses underserved maternal HF including in LMICs (peripartum cardiomyopathy, genetic cardiomyopathies in pregnancy).

• TR-011 · PMID 42216660 · SGLT2 Inhibitors in the Management of Diabetic Retinopathy: A Literature Review. · 4/10 · Drug Development
  Babović S et al. · Pharmazie · Reviews preclinical evidence supporting SGLT2i retinal protection; calls for RCTs with ophthalmic endpoints.

Aging / Longevity

• TR-008 · PMID 42216479 · AQP4 genetic variants and Alzheimer's disease phenotypes — direct and sleep-moderated effects. · 6/10 · Genomics/Precision Medicine
  Porter T et al. (AIBL Research Group) · Alzheimers Dement · AQP4 variants associate directly and via sleep disruption with AD phenotypes; supports glymphatic pathway + sleep intervention trials.

• TR-012 · PMID 42216459 · P300 Event-Related Potentials as Cognitive Biomarkers: A Systematic Review. · 5/10 · Diagnostics
  Gkintoni E et al. · Rev Neurol · Systematic review confirming P300 utility across neurological disorders; standardization gaps limit clinical translation.

Precision Oncology / Genomics

• TR-013 · PMID 42216580 · Multi-Omics Analysis Reveals RPS8 as a Prognostic Biomarker in Hepatocellular Carcinoma. · 4/10 · Genomics
  Zhu L et al. · BioFactors · Multi-omics + in vitro; exploratory ribosomal protein as HCC target.

Early Cancer Detection (Sentinel)

• TR-009 · PMID 42216438 · Personalised and Gamified Digital Decision Aid for CRC Screening: An RCT Pilot. · 5/10 · Prevention
  Mattia C et al. · Cancer Med · RCT; only 1% of invited population downloaded app; 17% met informed-choice criteria. Key finding: digital engagement tools alone cannot solve screening literacy gaps.

💡 UNSOLICITED FINDS

None meeting high-signal criteria outside watchlist. PMID 42216438 (CRC screening digital DA RCT) flagged as sentinel find but topic-adjacent (scored STANDARD, already listed above).

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 6 (TR-001, 002, 003, 005, 007, 014)
• Genomics/Precision Medicine: 3 (TR-001, 008, 013)
• Diagnostics: 2 (TR-006, 012)
• Drug Development: 2 (TR-011, 014)
• Prevention / Public Health: 2 (TR-009, 010)

By evidence maturity:

• Validated: 4 (TR-001, 003, 004, 005)
• Exploratory: 9 (TR-002, 006, 007, 008, 009, 011, 012, 013, 014)
• Validated + Exploratory (review): 1 (TR-010)

By watchlist topic — reviewed / kept / highest score:

By source type: peer_reviewed: 14 | preprint: 0

Topics with zero 8+ articles this run: Hematologic malignancies, CBC/ML hematology, AI/ML diagnostics, Aging/longevity, Rare diseases

🔧 RUN NOTES

• Window overlap: PubMed CRDT date filter is day-based; articles indexed 2026-05-30T00:00–06:37 UTC fall within today's query but before yesterday's stated window end (09:00 UTC). No PMID overlap confirmed with prior run's emitted list.
• CBC/ML topic: zero on-topic articles today. All 5 retrieved articles were off-topic (osteoporosis/pollution, SLE, pancreatitis). The query's broad "hematology" term matched many unrelated articles. Recommend tightening to include 'hematologic malignancy' OR 'leukemia' with specific CBC parameters (WBC differential, neutrophil-lymphocyte ratio, etc.) for future runs.
• Rare diseases query returned zero results. No window expansion triggered because aggregate watchlist hits >5. ATTR-CM (high unmet need) captured via cardiovascular topic.
• T1 (hematologic) false positives: PMID 42216646 and 42216637 (J Integr Neurosci) matched due to abbreviation artifacts in query (AML/CLL matching in other contexts). Discarded after summary review.
• T7 (cardiovascular) false positive: PMID 42216684 (J Vet Diagn Invest — racehorse sudden death). Discarded on title review. The broad 'heart failure' term in the query continues to capture veterinary articles; consider restricting with NOT veterinary[SH].
• humans[MeSH] filter applied to aging/longevity topic as per 2026-05-04 run annotation. Filter reduced non-human noise effectively (7 results, all human-relevant).
• PMID 42216561 (AML Br J Haematol): No abstract available (article status: "as supplied by publisher"). Per scoring rules, title-only articles capped at 3/10; record noted but not included in classified output. Worth re-checking in next run when abstract is available.
• Prior 7-day trend for CBC/ML: This topic has produced zero standard+ articles on consecutive weekend runs (May 31, no signal; May 30, resolved with PMID 42216477). Weekday indexing tends to produce more signal for this topic.